Measurement and Clinical Utility of βCTX in Serum and Plasma

Stephen Anthony Paul Chubb, Samuel D. Vasikaran

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Biochemical markers of bone turnover (BTM) are released during bone remodeling and can be measured in blood or urine as noninvasive surrogate markers for the bone remodeling rate. The C-terminal cross-linked telopeptide of type I collagen (βCTX) is released during bone resorption and is specific to bone tissue. Assays have been developed to measure βCTX in blood and in urine; most current use of βCTX measurement for research and in clinical practice is performed on a blood sample. Method-specific differences for serum and plasma βCTX have led to initiatives to standardize or harmonize βCTX commercial assays. βCTX demonstrates significant biological variation due to circadian rhythm and effect of food which can be minimized by standardized sample collection in the fasting state in the morning. While βCTX predicts fracture risk independent of bone mineral density, lack of data has precluded its inclusion in fracture risk calculators. The changes seen in βCTX with antiresorptive therapies have been well characterized and this has led to its widespread use for monitoring therapy in osteoporosis. However, more fracture-based data on appropriate treatment goals for monitoring need to be developed. Evidence is lacking for the use of βCTX in managing "drug holidays" of bisphosphonate treatment in osteoporosis or risk stratifying those at increased risk of developing osteonecrosis of the jaw. βCTX is useful as an adjunct to imaging techniques for the diagnosis of Paget's disease of bone and for monitoring therapy and detecting recurrence. βCTX also shows promise in the management of metastatic bone disease.

Original languageEnglish
Pages (from-to)97-134
JournalAdvances in Clinical Chemistry
Volume81
DOIs
Publication statusPublished - 2017

Fingerprint

Bone Remodeling
Bone
Plasmas
Serum
Osteoporosis
Biomarkers
Urine
Osteitis Deformans
Holidays
Blood
Osteonecrosis
Bone Diseases
Diphosphonates
Bone Resorption
Circadian Rhythm
Collagen Type I
Jaw
Bone Density
Monitoring
Assays

Cite this

@article{9fb59147fe1a472b924b7259303b0578,
title = "Measurement and Clinical Utility of βCTX in Serum and Plasma",
abstract = "Biochemical markers of bone turnover (BTM) are released during bone remodeling and can be measured in blood or urine as noninvasive surrogate markers for the bone remodeling rate. The C-terminal cross-linked telopeptide of type I collagen (βCTX) is released during bone resorption and is specific to bone tissue. Assays have been developed to measure βCTX in blood and in urine; most current use of βCTX measurement for research and in clinical practice is performed on a blood sample. Method-specific differences for serum and plasma βCTX have led to initiatives to standardize or harmonize βCTX commercial assays. βCTX demonstrates significant biological variation due to circadian rhythm and effect of food which can be minimized by standardized sample collection in the fasting state in the morning. While βCTX predicts fracture risk independent of bone mineral density, lack of data has precluded its inclusion in fracture risk calculators. The changes seen in βCTX with antiresorptive therapies have been well characterized and this has led to its widespread use for monitoring therapy in osteoporosis. However, more fracture-based data on appropriate treatment goals for monitoring need to be developed. Evidence is lacking for the use of βCTX in managing {"}drug holidays{"} of bisphosphonate treatment in osteoporosis or risk stratifying those at increased risk of developing osteonecrosis of the jaw. βCTX is useful as an adjunct to imaging techniques for the diagnosis of Paget's disease of bone and for monitoring therapy and detecting recurrence. βCTX also shows promise in the management of metastatic bone disease.",
keywords = "Antiresorptive therapy, Biochemical markers of bone turnover, Bone remodeling, C-terminal cross-linked telopeptide of type I collagen, CTX, Fracture risk assessment, Osteoporosis, Paget's disease",
author = "Chubb, {Stephen Anthony Paul} and Vasikaran, {Samuel D.}",
year = "2017",
doi = "10.1016/bs.acc.2017.01.003",
language = "English",
volume = "81",
pages = "97--134",
journal = "Advances in Clinical Chemistry",
issn = "0065-2423",
publisher = "Academic Press",

}

Measurement and Clinical Utility of βCTX in Serum and Plasma. / Chubb, Stephen Anthony Paul; Vasikaran, Samuel D.

In: Advances in Clinical Chemistry, Vol. 81, 2017, p. 97-134.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Measurement and Clinical Utility of βCTX in Serum and Plasma

AU - Chubb, Stephen Anthony Paul

AU - Vasikaran, Samuel D.

PY - 2017

Y1 - 2017

N2 - Biochemical markers of bone turnover (BTM) are released during bone remodeling and can be measured in blood or urine as noninvasive surrogate markers for the bone remodeling rate. The C-terminal cross-linked telopeptide of type I collagen (βCTX) is released during bone resorption and is specific to bone tissue. Assays have been developed to measure βCTX in blood and in urine; most current use of βCTX measurement for research and in clinical practice is performed on a blood sample. Method-specific differences for serum and plasma βCTX have led to initiatives to standardize or harmonize βCTX commercial assays. βCTX demonstrates significant biological variation due to circadian rhythm and effect of food which can be minimized by standardized sample collection in the fasting state in the morning. While βCTX predicts fracture risk independent of bone mineral density, lack of data has precluded its inclusion in fracture risk calculators. The changes seen in βCTX with antiresorptive therapies have been well characterized and this has led to its widespread use for monitoring therapy in osteoporosis. However, more fracture-based data on appropriate treatment goals for monitoring need to be developed. Evidence is lacking for the use of βCTX in managing "drug holidays" of bisphosphonate treatment in osteoporosis or risk stratifying those at increased risk of developing osteonecrosis of the jaw. βCTX is useful as an adjunct to imaging techniques for the diagnosis of Paget's disease of bone and for monitoring therapy and detecting recurrence. βCTX also shows promise in the management of metastatic bone disease.

AB - Biochemical markers of bone turnover (BTM) are released during bone remodeling and can be measured in blood or urine as noninvasive surrogate markers for the bone remodeling rate. The C-terminal cross-linked telopeptide of type I collagen (βCTX) is released during bone resorption and is specific to bone tissue. Assays have been developed to measure βCTX in blood and in urine; most current use of βCTX measurement for research and in clinical practice is performed on a blood sample. Method-specific differences for serum and plasma βCTX have led to initiatives to standardize or harmonize βCTX commercial assays. βCTX demonstrates significant biological variation due to circadian rhythm and effect of food which can be minimized by standardized sample collection in the fasting state in the morning. While βCTX predicts fracture risk independent of bone mineral density, lack of data has precluded its inclusion in fracture risk calculators. The changes seen in βCTX with antiresorptive therapies have been well characterized and this has led to its widespread use for monitoring therapy in osteoporosis. However, more fracture-based data on appropriate treatment goals for monitoring need to be developed. Evidence is lacking for the use of βCTX in managing "drug holidays" of bisphosphonate treatment in osteoporosis or risk stratifying those at increased risk of developing osteonecrosis of the jaw. βCTX is useful as an adjunct to imaging techniques for the diagnosis of Paget's disease of bone and for monitoring therapy and detecting recurrence. βCTX also shows promise in the management of metastatic bone disease.

KW - Antiresorptive therapy

KW - Biochemical markers of bone turnover

KW - Bone remodeling

KW - C-terminal cross-linked telopeptide of type I collagen

KW - CTX

KW - Fracture risk assessment

KW - Osteoporosis

KW - Paget's disease

UR - http://www.scopus.com/inward/record.url?scp=85012882344&partnerID=8YFLogxK

U2 - 10.1016/bs.acc.2017.01.003

DO - 10.1016/bs.acc.2017.01.003

M3 - Review article

VL - 81

SP - 97

EP - 134

JO - Advances in Clinical Chemistry

JF - Advances in Clinical Chemistry

SN - 0065-2423

ER -